Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MED.0000000000000253 http://scihub22266oqcxt.onion/10.1097/MED.0000000000000253 C4893781!4893781!27119752     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Endocrinol+Diabetes+Obes 2016 ; 23 (3): 264-70 Nephropedia Template TP {{tp|p=27119752|t=2016. Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer |pdf=|usr=}}{{27119752}} gab.com Text Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer JO: Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=27119752 #FOAvip Purpose of review: Androgen deprivation therapy is a cornerstone in the treatment of advanced prostate cancer and has extended the lives of countless patients. Unfortunately, many of these patients eventually succumb to metastatic castration-resistant prostate cancer (mCRPC). The efficacy of abiraterone acetate (Zytiga) and enzalutamide (Enza, Xtandi) in the mCRPC setting prove that these tumors remain androgen-driven. We review recent studies that have shown that intratumoral androgen biosynthesis plays a significant role in the ever-evolving mCRPC tumor and we discuss the therapeutic implications of these findings. Recent findings: A novel abiraterone metabolite, D4A, possesses robust anti-tumor activity in rodent models via the inhibition of androgen biosynthetic enzymes and antagonism of AR. The TMPRSS2:ERG fusion drives AKR1C3 expression and activity to facilitate androgen biosynthesis and activate the androgen receptor (AR) in prostate cancer. Intracrine androgen formation and AKR1C3 expression and activity have been found to confer resistance to enzalutamide. Summary: These studies highlight the significant role that intratumoral androgen biosynthesis plays in the mCRPC tumor. The therapeutic implications include the inhibition of AKR1C3 in tumors that become resistant to current drugs such as AA or Enza and the potential administration of D4A as a mCRPC therapeutic. Twit Text FOAVip Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer ????Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=27119752 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27119752 #FOAvip English Wikipedia <ref>{{Cite pmid|27119752}}</ref> Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer #MMPMID27119752 Penning TM; Tamae D Curr Opin Endocrinol Diabetes Obes 2016[Jun]; 23 (3): 264-70 PMID27119752show ga Purpose of review: Androgen deprivation therapy is a cornerstone in the treatment of advanced prostate cancer and has extended the lives of countless patients. Unfortunately, many of these patients eventually succumb to metastatic castration-resistant prostate cancer (mCRPC). The efficacy of abiraterone acetate (Zytiga) and enzalutamide (Enza, Xtandi) in the mCRPC setting prove that these tumors remain androgen-driven. We review recent studies that have shown that intratumoral androgen biosynthesis plays a significant role in the ever-evolving mCRPC tumor and we discuss the therapeutic implications of these findings. Recent findings: A novel abiraterone metabolite, D4A, possesses robust anti-tumor activity in rodent models via the inhibition of androgen biosynthetic enzymes and antagonism of AR. The TMPRSS2:ERG fusion drives AKR1C3 expression and activity to facilitate androgen biosynthesis and activate the androgen receptor (AR) in prostate cancer. Intracrine androgen formation and AKR1C3 expression and activity have been found to confer resistance to enzalutamide. Summary: These studies highlight the significant role that intratumoral androgen biosynthesis plays in the mCRPC tumor. The therapeutic implications include the inhibition of AKR1C3 in tumors that become resistant to current drugs such as AA or Enza and the potential administration of D4A as a mCRPC therapeutic. äCurrent advances in intratumoral androgen metabolism in castration-res(epmc).pdf DeepDyve Pubget Overpricing